Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Unknown 3

Sponsor Class

OTHER 1728INDUSTRY 713NIH 341NETWORK 159OTHER_GOV 32FED 4UNKNOWN 3INDIV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Extranodal NK-T-Cell 4Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Recurrence 1Philadelphia Chromosome 1Lymphoma, T-Cell, Peripheral 1Hodgkin Disease 1

Interventions

Rituximab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
UNKNOWN × Lymphoma × Lymphoid × Clear all
NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Recurrence

NCT04511351 2020-08-13

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

ChineseAMS

Phase NA Unknown
76 enrolled
Lymphoid

Lymphoma

NCT03731390 2018-11-06

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

ChineseAMS

Phase 1 Unknown
30 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡